ICICI Prudential Asset Management Co Ltd Has $543,000 Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

ICICI Prudential Asset Management Co Ltd boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 18.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,074 shares of the company’s stock after purchasing an additional 167 shares during the quarter. ICICI Prudential Asset Management Co Ltd’s holdings in IDEXX Laboratories were worth $543,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of IDXX. Crewe Advisors LLC acquired a new stake in shares of IDEXX Laboratories during the 1st quarter worth $26,000. Ridgewood Investments LLC bought a new stake in IDEXX Laboratories during the second quarter worth about $27,000. Institutional & Family Asset Management LLC acquired a new stake in IDEXX Laboratories during the second quarter worth about $28,000. E Fund Management Hong Kong Co. Ltd. increased its holdings in IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after buying an additional 57 shares during the period. Finally, Mowery & Schoenfeld Wealth Management LLC increased its holdings in IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after buying an additional 60 shares during the period. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on IDXX. Barclays reduced their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Piper Sandler reaffirmed a “neutral” rating and issued a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. JPMorgan Chase & Co. lowered their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday, October 10th. Finally, BTIG Research assumed coverage on IDEXX Laboratories in a research report on Thursday, July 25th. They issued a “buy” rating and a $580.00 target price on the stock. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $552.38.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $429.82 on Thursday. The business has a 50-day simple moving average of $471.09 and a two-hundred day simple moving average of $484.18. IDEXX Laboratories, Inc. has a 12-month low of $404.74 and a 12-month high of $583.39. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The stock has a market cap of $35.20 billion, a PE ratio of 41.45, a PEG ratio of 3.72 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. During the same period in the previous year, the firm posted $2.53 EPS. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. Analysts anticipate that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.